Abstract
Herbal medicines are often used in combination with conventional drugs, and this may give rise to the potential of harmful herb-drug interactions. This paper updates our knowledge on clinical herb-drug interactions with an emphasis of the mechanistic and clinical consideration. In silico, in vitro, animal and human studies are often used to predict and/or identify drug interactions with herbal remedies. To date, a number of clinically important herb-drug interactions have been reported, but many of them are from case reports and limited clinical observations. Common herbal medicines that interact with drugs include St John’s wort (Hypericum perforatum), ginkgo (Ginkgo biloba), ginger (Zingiber officinale), ginseng (Panax ginseng), and garlic (Allium sativum). For example, St John's wort significantly reduced the area under the plasma concentration-time curve (AUC) and blood concentrations of cyclosporine, midazolam, tacrolimus, amitriptyline, digoxin, indinavir, warfarin, phenprocoumon and theophylline. The common drugs that interact with herbal medicines include warfarin, midazolam, digoxin, amitriptyline, indinavir, cyclosporine, tacrolimus and irinotecan. Herbal medicines may interact with drugs at the intestine, liver, kidneys, and targets of action. Importantly, many of these drugs have very narrow therapeutic indices. Most of them are substrates for cytochrome P450s (CYPs) and/or P-glycoprotein (P-gp). The underlying mechanisms for most reported herb-drug interactions are not fully understood, and pharmacokinetic and/or pharmacodynamic mechanisms are implicated in many of these interactions. In particular, enzyme induction and inhibition may play an important role in the occurrence of some herbdrug interactions. Because herb-drug interactions can significantly affect circulating levels of drug and, hence, alter the clinical outcome, the identification of herb-drug interactions has important implications.
Keywords: Herb medicine, drug interaction, toxicity, pharmacokinetics, CYP, P-gp, Interactions, Herbal medicines, conventional drugs, cytochrome P450s, P-glycoprotein, Toxicity, Ginkgo biloba, St John’s wort, ethnic groups
Current Drug Metabolism
Title:Herb-Drug Interactions and Mechanistic and Clinical Considerations
Volume: 13 Issue: 5
Author(s): Xiao-Wu Chen, Kevin B. Sneed, Si-Yuan Pan, Chuanhai Cao, Jagat R. Kanwar, Helen Chew and Shu- Feng Zhou
Affiliation:
Keywords: Herb medicine, drug interaction, toxicity, pharmacokinetics, CYP, P-gp, Interactions, Herbal medicines, conventional drugs, cytochrome P450s, P-glycoprotein, Toxicity, Ginkgo biloba, St John’s wort, ethnic groups
Abstract: Herbal medicines are often used in combination with conventional drugs, and this may give rise to the potential of harmful herb-drug interactions. This paper updates our knowledge on clinical herb-drug interactions with an emphasis of the mechanistic and clinical consideration. In silico, in vitro, animal and human studies are often used to predict and/or identify drug interactions with herbal remedies. To date, a number of clinically important herb-drug interactions have been reported, but many of them are from case reports and limited clinical observations. Common herbal medicines that interact with drugs include St John’s wort (Hypericum perforatum), ginkgo (Ginkgo biloba), ginger (Zingiber officinale), ginseng (Panax ginseng), and garlic (Allium sativum). For example, St John's wort significantly reduced the area under the plasma concentration-time curve (AUC) and blood concentrations of cyclosporine, midazolam, tacrolimus, amitriptyline, digoxin, indinavir, warfarin, phenprocoumon and theophylline. The common drugs that interact with herbal medicines include warfarin, midazolam, digoxin, amitriptyline, indinavir, cyclosporine, tacrolimus and irinotecan. Herbal medicines may interact with drugs at the intestine, liver, kidneys, and targets of action. Importantly, many of these drugs have very narrow therapeutic indices. Most of them are substrates for cytochrome P450s (CYPs) and/or P-glycoprotein (P-gp). The underlying mechanisms for most reported herb-drug interactions are not fully understood, and pharmacokinetic and/or pharmacodynamic mechanisms are implicated in many of these interactions. In particular, enzyme induction and inhibition may play an important role in the occurrence of some herbdrug interactions. Because herb-drug interactions can significantly affect circulating levels of drug and, hence, alter the clinical outcome, the identification of herb-drug interactions has important implications.
Export Options
About this article
Cite this article as:
Chen Xiao-Wu, B. Sneed Kevin, Pan Si-Yuan, Cao Chuanhai, R. Kanwar Jagat, Chew Helen and Zhou Shu- Feng, Herb-Drug Interactions and Mechanistic and Clinical Considerations, Current Drug Metabolism 2012; 13 (5) . https://dx.doi.org/10.2174/1389200211209050640
DOI https://dx.doi.org/10.2174/1389200211209050640 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Medicinal Plants Towards Modeling Skin Cancer
Current Drug Targets Copy Number Variations with Isolated Fetal Ventriculomegaly
Current Molecular Medicine Natural Antioxidants in Wheat Sprout Extracts
Current Organic Chemistry Synthesis and Biological Interest of Structured Docosahexaenoic Acid–Containing Triacylglycerols and Phospholipids
Current Organic Chemistry Role of Open Source Tools and Resources in Virtual Screening for Drug Discovery
Combinatorial Chemistry & High Throughput Screening Eplerenone, a New Selective Aldosterone Blocker
Current Pharmaceutical Design Insulin Resistance as a Proinflammatory State: Mechanisms, Mediators, and Therapeutic Interventions
Current Drug Targets Copper as a Biocidal Tool
Current Medicinal Chemistry Physico-chemical and Biological Evaluation of Flavonols: Fisetin, Quercetin and Kaempferol Alone and Incorporated in beta Cyclodextrins
Anti-Cancer Agents in Medicinal Chemistry The Effect of Acute Hypoxia on Excitability in the Heart and the L-Type Calcium Channel as a Therapeutic Target
Current Drug Discovery Technologies Pharmacophore-based Screening for Identification of Human Acyl-CoA Cholesterol Acyltransferase Inhibitors: An In-silico Study
Letters in Drug Design & Discovery Can an Apple a Day Keep the Doctor Away?
Current Pharmaceutical Design Natural Products in Regression and Slowing of Progression of Atherosclerosis
Current Pharmaceutical Biotechnology Biologic Therapy in Psoriasis: Safety Profile
Current Drug Safety Cardiac Complications in Hypertension and Diabetes: Role of Sympathetic Nervous Activity
Current Hypertension Reviews Efficacy of Adjunctive Brexpiprazole in Patients with Major Depressive Disorder: A Clinical Overview
Current Psychiatry Reviews Dietary Small Molecules and Large-Scale Gene Expression Studies: An Experimental Approach for Understanding their Beneficial Effects on the Development of Malignant and Non-Malignant Proliferative Diseases
Current Medicinal Chemistry Smoking and Atherosclerosis: Mechanisms of Disease and New Therapeutic Approaches
Current Medicinal Chemistry CD93 and Related Family Members: Their Role in Innate Immunity
Current Drug Targets Mouse Models of Autoimmune Diseases - Autoimmune Myocarditis
Current Pharmaceutical Design